Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Overview
  • Published:

Targeting the gut to treat obesity and its metabolic comorbidities: focus on bariatric surgery - view from the chair

Abstract

Over the past decade, bariatric surgery emerged as the most effective treatment modality for obesity and its complications, especially type 2 diabetes. Initially introduced on the basis of their capacity to restrict food intake and/or induce dietary fat malabsorption, the current bariatric surgery procedures result in many more physiological changes that may also partly explain their potent and sustained anti-obesity and anti-diabetic effects. In the session 2 of the 17th International Symposium of the Université Laval Research Chair in Obesity, outstanding speakers have provided insight into novel clinical and pathophysiological aspects in bariatric surgery. Dr Blandine Laferrère discussed the growing body of evidence implicating incretin hormones in the anti-diabetic effects of bariatric surgery and Dr Hans-Rudolf Berthoud explored emerging evidence suggesting that bariatric surgery may reset the defended body mass set point. As data are rapidly accruing about the beneficial effects of bariatric surgery, these procedures not only take a greater place in clinical practice, but they also offer outstanding occasions to peek into the intricate and complex links between diet and gastrointestinal track, and obesity and its complications.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342–362.

    Article  CAS  Google Scholar 

  2. Mechanick JI, Youdim A, Jones DB, Timothy Garvey W, Hurley DL, Molly McMahon M et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update. Surg Obes Relat Dis 2013; 9: 159–191.

    Article  Google Scholar 

  3. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum DR, Belle SH, King WC, Wahed AS, Berk P et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361: 445–454.

    Article  Google Scholar 

  4. Camps SG, Verhoef SP, Westerterp KR . Weight loss, weight maintenance, and adaptive thermogenesis. Am J Clin Nutr 2013; 97: 990–994.

    Article  CAS  Google Scholar 

  5. van Gemert WG, Westerterp KR, Greve JW, Soeters PB . Reduction of sleeping metabolic rate after vertical banded gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 343–348.

    Article  CAS  Google Scholar 

  6. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741–752.

    Article  Google Scholar 

  7. Sjostrom L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden A et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311: 2297–2304.

    Article  Google Scholar 

  8. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567–1576.

    Article  CAS  Google Scholar 

  9. Mingrone G, Panunzi S, De GA, Guidone C, Iaconelli A, Leccesi L et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577–1585.

    Article  CAS  Google Scholar 

  10. Bradley D, Magkos F, Klein S . Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology 2012; 143: 897–912.

    Article  CAS  Google Scholar 

  11. Plourde CE, Grenier-Larouche T, Caron-Dorval D, Biron S, Marceau S, Lebel S et al. Biliopancreatic diversion with duodenal switch improves insulin sensitivity and secretion through caloric restriction. Obesity 2014; 22: 1838–1846.

    Article  CAS  Google Scholar 

  12. Dutia R, Brakoniecki K, Bunker P, Paultre F, Homel P, Carpentier AC et al. Limited recovery of beta-cell function after gastric bypass despite clinical diabetes remission. Diabetes 2014; 63: 1214–1223.

    Article  CAS  Google Scholar 

  13. Isbell JM, Tamboli RA, Hansen EN, Saliba J, Dunn JP, Phillips SE et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes care 2010; 33: 1438–1442.

    Article  CAS  Google Scholar 

  14. Kunach M, Noll C, Phoenix S, Guerin B, Baillargeon JP, Turcotte EE et al. Effect of sex and impaired glucose tolerance on organ-specific dietary fatty acid metabolism in humans. Diabetes 2015; 64: 2432–2441.

    Article  CAS  Google Scholar 

  15. Carpentier AC . The 2012 CDA-CIHR INMD Young Investigator Award Lecture: dysfunction of adipose tissues and the mechanisms of ectopic fat deposition in type 2 diabetes. Can J Diabetes 2013; 37: 109–114.

    Article  Google Scholar 

  16. Tremaroli V, Karlsson F, Werling M, Stahlman M, Kovatcheva-Datchary P, Olbers T et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 2015; 22: 228–238.

    Article  CAS  Google Scholar 

  17. Penney NC, Kinross J, Newton RC, Purkayastha S . The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes 2015; 39: 1565–1574.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Publication of this article was sponsored by the Université Laval’s Research Chair in Obesity in an effort to inform the public on the causes, consequences, treatments and prevention of obesity.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A C Carpentier.

Ethics declarations

Competing interests

ACC is the recipient of the CIHR-GSK Chair in Diabetes, and owns equity in Biblaire GGCACC has received grant support from Caprion, UniQure, GlaxoSmithKline, Canadian Institutes of Health Research, Canadian Diabetes Association, Heart and Stroke Foundation of Canada Faculty of Medicine and Health Sciences (funded by Merck Canada grant) and Fonds de recherche du Québec—Santé. The author declared no competing interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carpentier, A. Targeting the gut to treat obesity and its metabolic comorbidities: focus on bariatric surgery - view from the chair. Int J Obes Supp 6 (Suppl 1), S6–S7 (2016). https://doi.org/10.1038/ijosup.2016.7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijosup.2016.7

Search

Quick links